Aprogen Medicines Inc. (KOSE:A007460) signed a merger contract to acquire remaining unknown stake in Aprogen, Inc. on September 15, 2021. Under the transaction, Aprogen Medicines will issue 10.8654060 shares for every 1 share of Aprogen, Inc. Post merger, Aprogen Medicines will be the surviving company and Aprogen, Inc. be merged with Aprogen Medicines. Merger is expected to complete on January 25, 2022.

As per revised schedule merger is expected to complete on February 15, 2022. As per revised schedule merger is expected to complete on March 11, 2022. As per revised schedule merger is expected to complete on June 8, 2022.

As of April 18, 2022, as per revised schedule merger is expected to complete on June 15, 2022. As of April 28, 2022, as per revised schedule merger is expected to complete on July 15, 2022.